2.Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”
Seren M. GEDALLOVICH ; Paul Y. KWO
Clinical and Molecular Hepatology 2024;30(4):677-681
4.Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”
Seren M. GEDALLOVICH ; Paul Y. KWO
Clinical and Molecular Hepatology 2024;30(4):677-681
6.Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”
Seren M. GEDALLOVICH ; Paul Y. KWO
Clinical and Molecular Hepatology 2024;30(4):677-681
8.Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”
Seren M. GEDALLOVICH ; Paul Y. KWO
Clinical and Molecular Hepatology 2024;30(4):677-681
Result Analysis
Print
Save
E-mail